journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Cancer

journal
https://www.readbyqxmd.com/read/29777975/geriatric-analysis-from-prodige-20-randomized-phase-ii-trial-evaluating-bevacizumab-chemotherapy-versus-chemotherapy-alone-in-older-patients-with-untreated-metastatic-colorectal-cancer
#1
T Aparicio, O Bouché, E Francois, F Retornaz, E Barbier, J Taieb, S Kirscher, P-L Etienne, R Faroux, F Khemissa Akouz, F El Hajbi, C Locher, Y Rinaldi, T Lecomte, S Lavau-Denes, M Baconnier, A Oden-Gangloff, D Genet, L Bedenne, E Paillaud
BACKGROUND: Older patients have frailty characteristics that impair the transposition of treatment results found in younger patients. Predictive factors are needed to help with treatment choices for older patients. The PRODIGE 20 study is a randomized phase II study that evaluated chemotherapy associated with bevacizumab (BEV) or not (CT) in patients aged 75 years or older. PATIENTS AND METHODS: Patients underwent a geriatric assessment at randomization and at each evaluation...
May 16, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29759655/re-no-overdiagnosis-in-the-norwegian-breast-cancer-screening-program-estimated-by-combining-record-linkage-and-questionnaire-information-in-the-norwegian-women-and-cancer-study
#2
LETTER
Eiliv Lund, Aurelie Nakamura, Jean-Christophe Thalabard
No abstract text is available yet for this article.
May 11, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29759654/letter-comments-on-ejc-published-paper-no-overdiagnosis-in-the-norwegian-breast-cancer-screening-program-estimated-by-combining-record-linkage-and-questionnaire-information-in-the-norwegian-women-and-cancer-study
#3
LETTER
https://www.readbyqxmd.com/read/29743138/ctla-4-gene-variant-1661a-g-may-predict-the-onset-of-endocrine-adverse-events-in-metastatic-melanoma-patients-treated-with-ipilimumab
#4
LETTER
Paola Queirolo, Beatrice Dozin, Anna Morabito, Barbara Banelli, Roberta Carosio, Vincenzo Fontana, Pier Francesco Ferrucci, Chiara Martinoli, Emilia Cocorocchio, Paolo A Ascierto, Gabriele Madonna, Ester Simeone, Federica De Galitiis, Gian Carlo Antonini Cappellini, Paolo Marchetti, Michele Guida, Stefania Tommasi, Laura Ghilardi, Barbara Merelli, Paolo Fava, Simona Osella-Abate, Massimo Guidoboni, Massimo Romani, Diego Ferone, Francesco Spagnolo, Maria Pia Pistillo
No abstract text is available yet for this article.
May 7, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29739641/avoidable-cancers-in-the-nordic-countries-the-impact-of-alcohol-consumption
#5
Therese M-L Andersson, Gerda Engholm, Eero Pukkala, Magnus Stenbeck, Laufey Tryggvadottir, Hans Storm, Elisabete Weiderpass
BACKGROUND: Alcohol consumption is an important and preventable cause of cancer. The aim of this study was to quantify the proportion of the cancer burden in the Nordic countries linked to alcohol and estimate the potential for cancer prevention by changes in alcohol consumption. METHODS: Using the Prevent macro-simulation model, the number of cancer cases in the Nordic countries over a 30-year period (2016-2045) was modelled for six sites, under different scenarios of changing alcohol consumption, and compared to the projected number of cases if constant alcohol consumption prevailed...
May 5, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29735378/more-is-more-pushing-chemoradiotherapy-of-oesophageal-squamous-cell-carcinoma-forward
#6
EDITORIAL
Florian Lordick
No abstract text is available yet for this article.
May 4, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29734047/efficacy-and-safety-of-single-agent-pan-human-epidermal-growth-factor-receptor-her-inhibitor-dacomitinib-in-locally-advanced-unresectable-or-metastatic-skin-squamous-cell-cancer
#7
S Cavalieri, F Perrone, R Miceli, P A Ascierto, L D Locati, C Bergamini, R Granata, S Alfieri, C Resteghini, D Galbiati, A Busico, N Paielli, R Patuzzo, A Maurichi, G Gallino, R Ruggeri, L Mariani, M Palla, L Licitra, P Bossi
BACKGROUND: In recurrent or metastatic (R/M) skin squamous cell cancer (sSCC) not amenable to radiotherapy (RT) or surgery, chemotherapy (CT) has a palliative intent and limited clinical responses. The role of oral pan-HER inhibitor dacomitinib in this setting was investigated within a clinical trial. METHODS: Patients with diagnosis of R/M sSCC were treated. Dacomitinib was started at a dose of 30 mg daily (QD) for 15 d, followed by 45 mg QD. Primary end-point was response rate (RR)...
May 4, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29734046/impact-of-neoadjuvant-chemotherapy-and-pathological-complete-response-on-eligibility-for-breast-conserving-surgery-in-patients-with-early-breast-cancer-a-meta-analysis
#8
Carmen Criscitiello, Mehra Golshan, William T Barry, Giulia Viale, Stephanie Wong, Michele Santangelo, Giuseppe Curigliano
PURPOSE: We conducted a meta-analysis of randomised trials evaluating pathological complete response (pCR) and surgical outcomes after neoadjuvant systemic therapy (NST) in patients with early breast cancer (EBC). PATIENTS AND METHODS: The primary outcome was breast-conserving surgery (BCT) rate. Secondary outcomes were pCR rate and association to BCT. Meta-analyses were performed using random effects models that use inverse-variance weighting for each treatment arm based on evaluable patients...
May 4, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29731230/the-international-cardioncology-society-one-trial-not-all-that-glitters-is-for-cardioncologists-only
#9
EDITORIAL
Giorgio Minotti
No abstract text is available yet for this article.
May 3, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29731229/immunotherapy-induced-addison-s-disease-a-rare-persistent-and-potentially-lethal-side-effect
#10
LETTER
S Hescot, M Haissaguerre, P Pautier, E Kuhn, M Schlumberger, A Berdelou
No abstract text is available yet for this article.
May 3, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29731228/role-of-perioperative-chemotherapy-in-soft-tissue-sarcomas-it-s-time-to-end-a-never-ending-story
#11
LETTER
A Italiano, E Stoeckle
No abstract text is available yet for this article.
May 3, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29731227/refining-the-use-of-cabazitaxel-in-metastatic-castrate-resistant-prostate-cancer
#12
Stéphane Culine
No abstract text is available yet for this article.
May 3, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29731226/low-level-postoperative-carcinoembryonic-antigen-improves-survival-outcomes-stratification-in-patients-with-stage-ii-colon-cancer-treated-with-standard-adjuvant-treatments
#13
LETTER
E Auclin, T André, J Taieb, M Benetkiewicz, A de Gramont, D Vernerey
No abstract text is available yet for this article.
May 3, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29729562/reporting-of-patient-characteristics-and-stratification-factors-in-phase-3-trials-investigating-first-line-systemic-treatment-of-metastatic-colorectal-cancer-a-systematic-review
#14
REVIEW
Kaitlyn K H Goey, Remi Mahmoud, Halfdan Sørbye, Bengt Glimelius, Claus-Henning Köhne, Daniel J Sargent, Cornelis J A Punt, Martijn G H van Oijen, Miriam Koopman
BACKGROUND: Patient characteristics and stratification factors are important factors influencing trial outcomes. Uniform reporting on these parameters would facilitate cross-study comparisons and extrapolation of trial results to clinical practice. In 2007, standardisation on patient characteristics reporting and stratification in metastatic colorectal cancer (mCRC) trials was proposed. We investigated the reporting of prognostic factors and implementation of this proposal in mCRC trials published from 2005 to 2016...
May 2, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29705511/checkpoint-blockade-after-kidney-transplantation
#15
LETTER
Mathieu Lesouhaitier, Caroline Dudreuilh, Mathilde Tamain, Nada Kanaan, Elodie Bailly, Delphine Legoupil, Clement Deltombe, Peggy Perrin, Guillaume Manson, Cécile Vigneau, Roch Houot
No abstract text is available yet for this article.
April 26, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29705530/prevalence-of-beliefs-about-actual-and-mythical-causes-of-cancer-and-their-association-with-socio-demographic-and-health-related-characteristics-findings-from-a-cross-sectional-survey-in-england
#16
Lion Shahab, Jennifer A McGowan, Jo Waller, Samuel G Smith
BACKGROUND: Literature on population awareness about actual causes of cancer is growing but comparatively little is known about the prevalence of people's belief concerning mythical causes of cancer. This study aimed to estimate the prevalence of these beliefs and their association with socio-demographic characteristics and health behaviours. METHODS: A survey containing validated measures of beliefs about actual and mythical cancer causes and health behaviours (smoking, alcohol consumption, physical activity, fruit and vegetable consumption, overweight) was administered to a representative English population sample (N = 1330)...
April 23, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29698933/detection-of-immune-related-adverse-events-by-medical-imaging-in-patients-treated-with-anti-programmed-cell-death-1
#17
Ahmed Mekki, Laurent Dercle, Philip Lichtenstein, Aurélien Marabelle, Jean-Marie Michot, Olivier Lambotte, Jérôme Le Pavec, Eleonora De Martin, Corinne Balleyguier, Stéphane Champiat, Samy Ammari
BACKGROUND: Programmed death receptor-1 blocking antibodies (anti-PD1) are a new standard of care in many cancer types. Patients benefit from improved survival but have the risk of immune-related adverse events (irAE). We evaluated if medical imaging procedures, used for anti-tumour response assessment, can detect irAEs. MATERIALS AND METHODS: All consecutive patients treated with anti-PD1 and with a medical imaging acquisition performed within 2 weeks with irAEs ≥2 were retrospectively included...
April 23, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29698932/a-new-look-at-the-international-duration-evaluation-of-adjuvant-therapy-idea-classification-defining-novel-predictive-and-prognostic-markers-in-stage-iii-colon-cancer
#18
Ofer Margalit, Ronac Mamtani, Yu-Xiao Yang, Kim A Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce Giantonio, Einat Shacham-Shmueli, Ben Boursi
BACKGROUND: The International Duration Evaluation of Adjuvant therapy (IDEA) pooled analysis compared 3 to 6 months of adjuvant chemotherapy for stage III colon cancer. The overarching goal was to reduce chemotherapy-related toxicity, mainly oxaliplatin-induced neuropathy. Patients were classified into low-risk and high-risk groups, suggesting that low-risk patients may be offered only 3 months of treatment. We aimed to evaluate the benefit of monotherapy versus doublet chemotherapy in low and high IDEA risk groups...
April 23, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29685343/weekly-versus-3-weekly-cabazitaxel-for-the-treatment-of-castration-resistant-prostate-cancer-a-randomised-phase-ii-trial-concab
#19
Jeffrey Yachnin, Bjørnar Gilje, Kristian Thon, Hemming Johansson, Yvonne Brandberg, Theocharis Panaretakis, Anders Ullén
AIM: Patients treated with cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) may experience dose delays and reductions or terminate treatment because of toxicity. A lower and more frequent dose of cabazitaxel could improve dose intensity. PATIENTS AND METHODS: This prospective, multi-center, phase II study randomly assigned 101 patients to Arm A, cabazitaxel Q3W, 25 mg/m2 or Arm B, Q1W, 10 mg/m2 5 of 6 weeks. The primary end-point was dose intensity, and we hypothesised that the experimental arm (Arm B) would result in a 20% absolute increase in the relative cumulative dose by week 18...
April 20, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29680363/the-new-world-of-biosimilars-in-oncology-translation-of-data-to-the-clinic
#20
EDITORIAL
Hope S Rugo, Javier Cortes
No abstract text is available yet for this article.
April 18, 2018: European Journal of Cancer
journal
journal
30413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"